Study published in NEJM shows breakthrough drug can benefit more people with cystic fibrosis
According to a study published in the New England Journal of Medicine and co-led by Deepika Polineni, M.D., MPH, associate professor of pulmonary, critical care and sleep medicine, Trikafta can provide additional benefit for cystic fibrosis patients who have genetic mutations that made them eligible for previously approved CFTR modulators.
The field of health care is moving from the inefficient, one-size-fits-all-patients' medicine of today toward the data-driven and customized medicine of tomorrow. We envision a future where diagnosis, prognosis, treatment and prevention are tailored to each patient's unique genetic and phenotypic information.
The vision of the Kansas Institute for Precision Medicine (KIPM) COBRE is to advance education and support discoveries that will transform health care in our region and beyond.